在克罗恩病患者的乌斯特基努马布诱导疗法后症状的演变
Jean-Frédéric Colombel1, Bruce E Sands1, Christopher Gasink2
1Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
概括
乌斯特基努马布在输液后几天内迅速改善克罗恩氏病的症状. 在第8周继续治疗显著提高了临床缓解率,直到第44周.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩病 (CD) 是一种慢性炎症性疾病.
- 乌斯特基努马布是一种已知的CD治疗方法.
- 了解症状改善的速度对患者至关重要.
研究的目的:
- 分析克罗恩氏病患者的乌斯特基努马布的反应动态.
- 评估症状改善的时间和临床结果.
主要方法:
- 一个随机对照试验,涉及静脉输入乌斯特基努马布诱导 (n=458) 或安慰剂 (n=457).
- 在第8周的响应者接受了皮下乌斯特基努马布维持剂;不响应者接受了延长的诱导.
- 评估了患者报告的结果 (便频率,疼痛,幸福感) 和CD活动指数.
主要成果:
- 与安慰剂相比,在注射后的第1天,便频率显著改善,在注射后的第10天,所有患者报告的症状都显著改善.
- 在第16周累计的临床缓解率为55.5%的生物素素患者和24.1%的先前生物失败患者.
- 在44周,高达66.7%的患者通过维持疗法实现了临床反应.
结论:
- 乌斯特基努马布可从输液后的第一天开始快速缓解症状.
- 临床结果在维持治疗后的第16周和第44周继续改善.
- 建议在第8周进行一致的治疗,无论第8周的临床状态或药理动力学如何.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
299
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
299
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
200
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
200
Inflammatory Bowel Disease I: Ulcerative Colitis
223
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
223
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
156
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
Chronic Bowel Disorders: Introduction
489
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
489


